All In Biotech

Drug Trial Radar · NCT02405091

Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Last checked: Nov 20, 2026Latest source record: Nov 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

167

Actual

Start

Mar 2015

Primary completion

Mar 2017

Study completion Mar 2017

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Apr 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 3, open-label, study to evaluate the safety and tolerability of NBI-98854 administered once daily (qd) for a total of 48 weeks of treatment. This study will enroll approximately 150 medically stable male and female subjects with clinical diagnoses of schizophrenia or schizoaffective disorder with neuroleptic-induced TD or mood disorder with neuroleptic-induced TD.

Conditions

  • Tardive Dyskinesia

Interventions

  • NBI-98854Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Monitored for Long-Term Safety of ValbenazineTime frame: 52 weeks

Locations

48 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Anaheim, California

  • Site not named

    Glendale, California

  • Site not named

    Irvine, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Oakland, California

  • Site not named

    San Bernardino, California

  • Site not named

    San Diego, California

  • Site not named

    Torrance, California

  • Site not named

    Hockessin, Delaware

  • Site not named

    Bradenton, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Kissimmee, Florida

  • Site not named

    Miami, Florida

  • Site not named

    North Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Honolulu, Hawaii

  • Site not named

    Chicago, Illinois

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Natick, Massachusetts

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Omaha, Nebraska

  • Site not named

    Nashua, New Hampshire

  • Site not named

    Buffalo, New York

  • Site not named

    New York, New York

  • Site not named

    Rochester, New York

  • Site not named

    High Point, North Carolina

  • Site not named

    Dayton, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Conshohocken, Pennsylvania

  • Site not named

    Norristown, Pennsylvania

  • Site not named

    Phoenixville, Pennsylvania

  • Site not named

    Scranton, Pennsylvania

  • Site not named

    DeSoto, Texas

  • Site not named

    Fort Worth, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Irving, Texas

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.